Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-08-13

Clinical Trial Update: Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating optimal protamine dosing for reversing heparin after cardiopulmonary bypass; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Protamine sulfate (protamine sulfate)

Snippet

Sponsor: University of Miami | Conditions: Coagulation; Intravascular | Phase 4 | Status: COMPLETED | Results posted: 2024-08-13